GAM
NKTR icon

Gotham Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Gotham Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,073
Closed -$5.95M – 1215
2018
Q4 		$5.95M Sell
12,073
-8,926
-43% -$5.39M 0.09% 298
2018
Q3 		$19.2M Buy
20,999
+20,725
+7,564% +$17.7M 0.27% 115
2018
Q2 		$201K Sell
274
-23
-8% -$26.5K ﹤0.01% 841
2018
Q1 		$473K Sell
297
-13
-4% -$16.7K 0.01% 722
2017
Q4 		$278K Buy
+310
New +$183K ﹤0.01% 829
2015
Q3 		– Sell
-90,928
Closed -$17.1M – 1001
2015
Q2 		$17.1M Buy
+90,928
New +$15.6M 0.14% 227

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gotham Asset Management's NKTR Position: Q1 2019 in Review

Gotham Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 12,073 shares — an estimated $5.95M sold.

Gotham Asset Management first reported a position in NKTR in Q2 2015 and held it in 6 quarters. The position peaked at $19.2M in Q3 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Gotham Asset Management reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Gotham Asset Management sold 12,073 Nektar Therapeutics shares in Q1 2019, an estimated $5.95M.
  • Gotham Asset Management first reported a position in Nektar Therapeutics in Q2 2015 and held it in 6 quarters.
  • Gotham Asset Management's Nektar Therapeutics position peaked at $19.2M in Q3 2018.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Gotham Asset Management's 13F filing for Q1 2019, filed 15 May 2019.